Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T0686 |
Orlistat
Ro-18-0647,奥利司他,Tetrahydrolipstatin |
Apoptosis; Others; Fatty Acid Synthase | Apoptosis; Metabolism; Others |
Orlistat (Tetrahydrolipstatin) 是一种不可逆的胰腺和胃脂肪酶抑制剂,也是一种脂肪酸合成酶抑制剂,可研究肥胖症,具有抗动脉粥样硬化作用。 | |||
T32212 |
Isoleucine orlistat, L-
L-Isoleucine orlistat,Orlistat related compound E |
||
Isoleucine orlistat, L- is a bioactive chemical. | |||
T35788 |
Orlistat Degradation Product (sodium salt)
|
||
Orlistat degradation product is a degradation product of the digestive lipase inhibitor orlistat . It is formed via hydrolytic and thermal degradation as well as digestion by human carboxyl ester lipase. | |||
T70882 |
Orlistat-d3
|
||
Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor. It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α/β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg/ml, respectively) but does not inhibit... | |||
T70880 |
TAK-137
|
||
TAK-137 is a novel AMPA receptor potentiator with little agonistic effect, producing antidepressant-like effect without causing psychotomimetic effects. |